Organization
Suzhou Transcenta Therapeutics
8 clinical trials
3 abstracts
Clinical trial
Phase I Clinical Trial on the Tolerability and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2022-06-08
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Nivolumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (Gastric/GEJ) AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-09-30
Clinical trial
A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-05-01
Abstract
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Fudan University Shanghai Cancer Center, Mary Crowley Cancer Research Center, Gabrail Cancer Center Research LLC, Transcenta Therapeutics, Princeton, NJ, Beijing Cancer Hospital, Beijing, China,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).Org: Suzhou Transcenta Therapeutics, Transcenta Holding, XEXUS Global Biopharma Clinical Development Consulting, LLC, Transcenta Therapeutics, Princeton, NJ, Beijing Cancer Hospital, Beijing, China,